Tasch James, Gonzalez-Zayaz Pedro
Graduate Medical Education, Arnot Ogden Medical Center, Elmira, USA.
Am J Case Rep. 2017 Apr 21;18:431-435. doi: 10.12659/AJCR.903507.
BACKGROUND Drug-induced immune hemolytic anemia (DIIHA) is a rare condition that may result from the administration of an antibiotic, most notably the cephalosporin class, commonly used in both the adult and pediatric populations. A delay in recognition by a provider may lead to continuation of the offending agent and possibly result in fatal outcomes. CASE REPORT We report the case of a 65-year-old woman on ceftriaxone infusions after being diagnosed with acute mitral valve endocarditis 3 weeks prior, which presented with severe anemia and bilateral transient vision loss. Being a Jehovah's Witness, the patient refused blood product transfusions and was managed with alternative therapies. The etiology of the symptoms was suspected to be a hemolytic anemia directly related to her ceftriaxone infusions. CONCLUSIONS This report demonstrates the importance of close vigilance while prescribing drugs known to cause hemolytic anemia. Although rare, drug-induced immune hemolytic anemia caused by ceftriaxone may be a potentially fatal condition, but with early recognition and withdrawal of the offending agent, successful treatment may ensue. Serological tests should be utilized to obtain a definitive diagnosis.
药物性免疫性溶血性贫血(DIIHA)是一种罕见病症,可能由使用抗生素引起,最常见的是头孢菌素类抗生素,在成人和儿童群体中均常用。医疗人员若识别延迟,可能导致致病药物持续使用,进而可能导致致命后果。病例报告:我们报告一例65岁女性病例,该患者在3周前被诊断为急性二尖瓣心内膜炎后接受头孢曲松输注治疗,出现严重贫血和双侧短暂性视力丧失。由于该患者是耶和华见证人,拒绝输血,采用替代疗法进行治疗。症状的病因怀疑是与她的头孢曲松输注直接相关的溶血性贫血。结论:本报告表明,在开具已知会导致溶血性贫血的药物时,密切监测非常重要。虽然罕见,但头孢曲松引起的药物性免疫性溶血性贫血可能是一种潜在致命病症,但通过早期识别和停用致病药物,可能实现成功治疗。应使用血清学检测以获得明确诊断。